Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin syndrome patients and concluding further development of nodular Basal Cell Carcinoma Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin syndrome patients and concluding further development of nodular Basal Cell Carcinoma